| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Abstract #10: Amyloid Precursor Protein Secretases As Therapeutic Targets for Spinal Cord Injury
|
Pajoohesh-Ganji, Ahdeah
|
|
2010
|
7 |
3 |
p. 331-
1 p.
|
article
|
| 2 |
Abstract #10: Amyloid Precursor Protein Secretases As Therapeutic Targets for Spinal Cord Injury
|
Pajoohesh-Ganji, Ahdeah
|
|
|
7 |
3 |
p. 331
|
article
|
| 3 |
Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis
|
Atassi, Nazem
|
|
2010
|
7 |
3 |
p. 329-
1 p.
|
article
|
| 4 |
Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis
|
Atassi, Nazem
|
|
|
7 |
3 |
p. 329
|
article
|
| 5 |
Abstract #12: Computerized Essential Tremor Spirography: Development of a Rater-Independent Outcome Measure for Clinical Trials
|
Haubenberger, Dietrich
|
|
2010
|
7 |
3 |
p. 332-
1 p.
|
article
|
| 6 |
Abstract #12: Computerized Essential Tremor Spirography: Development of a Rater-Independent Outcome Measure for Clinical Trials
|
Haubenberger, Dietrich
|
|
|
7 |
3 |
p. 332
|
article
|
| 7 |
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model
|
Goldberg-Zimring, Daniel
|
|
2010
|
7 |
3 |
p. 328-329
2 p.
|
article
|
| 8 |
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model
|
Goldberg-Zimring, Daniel
|
|
|
7 |
3 |
p. 328-329
|
article
|
| 9 |
Abstract #14: Development of a Novel Non-Anxiogenic Broad Spectrum Anti-Emetic
|
Alexander, Elaine
|
|
2010
|
7 |
3 |
p. 332-333
2 p.
|
article
|
| 10 |
Abstract #14: Development of a Novel Non-Anxiogenic Broad Spectrum Anti-Emetic
|
Alexander, Elaine
|
|
|
7 |
3 |
p. 332-333
|
article
|
| 11 |
Abstract #2: Diffusion Tensor Imaging As a Neuroprotection Outcome Metric in Multiple Sclerosis: Clinical Trial Sample Size Estimates
|
Fox, Robert J.
|
|
2010
|
7 |
3 |
p. 328-
1 p.
|
article
|
| 12 |
Abstract #2: Diffusion Tensor Imaging As a Neuroprotection Outcome Metric in Multiple Sclerosis: Clinical Trial Sample Size Estimates
|
Fox, Robert J.
|
|
|
7 |
3 |
p. 328
|
article
|
| 13 |
Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm
|
Gopal, Srihari
|
|
2010
|
7 |
3 |
p. 333-
1 p.
|
article
|
| 14 |
Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm
|
Gopal, Srihari
|
|
|
7 |
3 |
p. 333
|
article
|
| 15 |
Abstract #1: EVP-6124 Elicits Pro-Cognitive Effects in Alzheimer's Patients
|
Apter, Jeffrey T.
|
|
2010
|
7 |
3 |
p. 328-
1 p.
|
article
|
| 16 |
Abstract #1: EVP-6124 Elicits Pro-Cognitive Effects in Alzheimer's Patients
|
Apter, Jeffrey T.
|
|
|
7 |
3 |
p. 328
|
article
|
| 17 |
Abstract #9: Gender Related Outcome Differences after Experimental Mild Traumatic Brain Injury
|
Li, Shihong
|
|
2010
|
7 |
3 |
p. 331-
1 p.
|
article
|
| 18 |
Abstract #9: Gender Related Outcome Differences after Experimental Mild Traumatic Brain Injury
|
Li, Shihong
|
|
|
7 |
3 |
p. 331
|
article
|
| 19 |
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis
|
Arora, Ashish
|
|
2010
|
7 |
3 |
p. 329-
1 p.
|
article
|
| 20 |
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis
|
Arora, Ashish
|
|
|
7 |
3 |
p. 329
|
article
|
| 21 |
Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study
|
Guttuso Jr., Thomas
|
|
2010
|
7 |
3 |
p. 332-
1 p.
|
article
|
| 22 |
Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study
|
Guttuso Jr., Thomas
|
|
|
7 |
3 |
p. 332
|
article
|
| 23 |
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
|
Tauhid, Shahamat S.
|
|
2010
|
7 |
3 |
p. 329-330
2 p.
|
article
|
| 24 |
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
|
Tauhid, Shahamat S.
|
|
|
7 |
3 |
p. 329-330
|
article
|
| 25 |
Abstract #16: Optical Coherence Tomography As a Clinical Trial Outcome Measure in Multiple Sclerosis: Implications of Treating On-Study Relapses with Intravenous Methylprednisolone
|
Bermel, Robert
|
|
2010
|
7 |
3 |
p. 333-
1 p.
|
article
|
| 26 |
Abstract #16: Optical Coherence Tomography As a Clinical Trial Outcome Measure in Multiple Sclerosis: Implications of Treating On-Study Relapses with Intravenous Methylprednisolone
|
Bermel, Robert
|
|
|
7 |
3 |
p. 333
|
article
|
| 27 |
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010
|
Apter, Jeffrey T.
|
|
2010
|
7 |
3 |
p. 328-333
|
article
|
| 28 |
Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity?
|
Wesnes, Keith Andrew
|
|
2010
|
7 |
3 |
p. 331-332
2 p.
|
article
|
| 29 |
Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity?
|
Wesnes, Keith Andrew
|
|
|
7 |
3 |
p. 331-332
|
article
|
| 30 |
Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults
|
Cramer, Joyce
|
|
2010
|
7 |
3 |
p. 330-331
2 p.
|
article
|
| 31 |
Abstract #8: Trial Methodology of a Randomized, Double-blind, Parallel-Group Study Evaluating the Clinical Effectiveness of Carisbamate, Topiramate, and Levetiracetam As Adjunctive Treatment of Partial Onset Seizures in Adults
|
Cramer, Joyce
|
|
|
7 |
3 |
p. 330-331
|
article
|
| 32 |
Abstract #7: Voxel Based Morphometry with DARTEL in Multiple Sclerosis
|
Ceccarelli, Antonia
|
|
2010
|
7 |
3 |
p. 330-
1 p.
|
article
|
| 33 |
Abstract #7: Voxel Based Morphometry with DARTEL in Multiple Sclerosis
|
Ceccarelli, Antonia
|
|
|
7 |
3 |
p. 330
|
article
|
| 34 |
Aripiprazole in autism spectrum disorders and fragile X syndrome
|
Erickson, Craig A.
|
|
2010
|
7 |
3 |
p. 258-263
|
article
|
| 35 |
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
|
Erickson, Craig A.
|
|
2010
|
7 |
3 |
p. 258-263
6 p.
|
article
|
| 36 |
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
|
Erickson, Craig A.
|
|
|
7 |
3 |
p. 258-263
|
article
|
| 37 |
Autism and oxytocin: New developments in translational approaches to therapeutics
|
Green, Joshua J.
|
|
2010
|
7 |
3 |
p. 250-257
|
article
|
| 38 |
Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics
|
Green, Joshua J.
|
|
2010
|
7 |
3 |
p. 250-257
8 p.
|
article
|
| 39 |
Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics
|
Green, Joshua J.
|
|
|
7 |
3 |
p. 250-257
|
article
|
| 40 |
Complementary and alternative medicine in autism: An evidence-based approach to negotiating safe and efficacious interventions with families
|
Akins, R. Scott
|
|
2010
|
7 |
3 |
p. 307-319
|
article
|
| 41 |
Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families
|
Akins, R. Scott
|
|
2010
|
7 |
3 |
p. 307-319
13 p.
|
article
|
| 42 |
Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families
|
Akins, R. Scott
|
|
|
7 |
3 |
p. 307-319
|
article
|
| 43 |
Contents
|
|
|
2010
|
7 |
3 |
p. ii-iii
nvt p.
|
article
|
| 44 |
Contents
|
|
|
|
7 |
3 |
p. ii-iii
|
article
|
| 45 |
Editorial Board
|
|
|
2010
|
7 |
3 |
p. i-
1 p.
|
article
|
| 46 |
Editorial Board
|
|
|
|
7 |
3 |
p. i
|
article
|
| 47 |
Fragile X: Leading the way for targeted treatments in autism
|
Wang, Lulu W.
|
|
2010
|
7 |
3 |
p. 264-274
|
article
|
| 48 |
Fragile X: Leading the Way for Targeted Treatments in Autism
|
Wang, Lulu W.
|
|
2010
|
7 |
3 |
p. 264-274
11 p.
|
article
|
| 49 |
Fragile X: Leading the Way for Targeted Treatments in Autism
|
Wang, Lulu W.
|
|
|
7 |
3 |
p. 264-274
|
article
|
| 50 |
Immune dysfunction in autism: A pathway to treatment
|
Careaga, Milo
|
|
2010
|
7 |
3 |
p. 283-292
|
article
|
| 51 |
Immune Dysfunction in Autism: A Pathway to Treatment
|
Careaga, Milo
|
|
2010
|
7 |
3 |
p. 283-292
10 p.
|
article
|
| 52 |
Immune Dysfunction in Autism: A Pathway to Treatment
|
Careaga, Milo
|
|
|
7 |
3 |
p. 283-292
|
article
|
| 53 |
Immune therapy in autism: Historical experience and future directions with immunomodulatory therapy
|
Chez, Michael G.
|
|
2010
|
7 |
3 |
p. 293-301
|
article
|
| 54 |
Immune Therapy in Autism: Historical Experience and Future Directions with Immunomodulatory Therapy
|
Chez, Michael G.
|
|
2010
|
7 |
3 |
p. 293-301
9 p.
|
article
|
| 55 |
Immune Therapy in Autism: Historical Experience and Future Directions with Immunomodulatory Therapy
|
Chez, Michael G.
|
|
|
7 |
3 |
p. 293-301
|
article
|
| 56 |
Improving the prediction of response to therapy in autism
|
Bent, Stephen
|
|
2010
|
7 |
3 |
p. 232-240
|
article
|
| 57 |
Improving the Prediction of Response to Therapy in Autism
|
Bent, Stephen
|
|
2010
|
7 |
3 |
p. 232-240
9 p.
|
article
|
| 58 |
Improving the Prediction of Response to Therapy in Autism
|
Bent, Stephen
|
|
|
7 |
3 |
p. 232-240
|
article
|
| 59 |
Medical comorbidities in autism: Challenges to diagnosis and treatment
|
Bauman, Margaret L.
|
|
2010
|
7 |
3 |
p. 320-327
|
article
|
| 60 |
Medical Comorbidities in Autism: Challenges to Diagnosis and Treatment
|
Bauman, Margaret L.
|
|
2010
|
7 |
3 |
p. 320-327
8 p.
|
article
|
| 61 |
Medical Comorbidities in Autism: Challenges to Diagnosis and Treatment
|
Bauman, Margaret L.
|
|
|
7 |
3 |
p. 320-327
|
article
|
| 62 |
Neurotherapeutics to publish primary research papers
|
Faden, Alan I.
|
|
2010
|
7 |
3 |
p. 229
|
article
|
| 63 |
Neurotherapeutics to Publish Primary Research Papers
|
Faden, Alan I.
|
|
2010
|
7 |
3 |
p. 229-
1 p.
|
article
|
| 64 |
Neurotherapeutics to Publish Primary Research Papers
|
Faden, Alan I.
|
|
|
7 |
3 |
p. 229
|
article
|
| 65 |
Shifting the paradigm for autism treatments
|
Hagerman, Randi J.
|
|
2010
|
7 |
3 |
p. 230-231
|
article
|
| 66 |
Shifting the Paradigm for Autism Treatments
|
Hagerman, Randi J.
|
|
2010
|
7 |
3 |
p. 230-231
2 p.
|
article
|
| 67 |
Shifting the Paradigm for Autism Treatments
|
Hagerman, Randi J.
|
|
|
7 |
3 |
p. 230-231
|
article
|
| 68 |
Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex
|
Vries, Petrus J. de
|
|
2010
|
7 |
3 |
p. 275-282
|
article
|
| 69 |
Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex
|
de Vries, Petrus J.
|
|
2010
|
7 |
3 |
p. 275-282
8 p.
|
article
|
| 70 |
Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex
|
de Vries, Petrus J.
|
|
|
7 |
3 |
p. 275-282
|
article
|
| 71 |
Tetrahydrobiopterin as a novel therapeutic intervention for autism
|
Frye, Richard E.
|
|
2010
|
7 |
3 |
p. 241-249
|
article
|
| 72 |
Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism
|
Frye, Richard E.
|
|
2010
|
7 |
3 |
p. 241-249
9 p.
|
article
|
| 73 |
Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism
|
Frye, Richard E.
|
|
|
7 |
3 |
p. 241-249
|
article
|
| 74 |
Tourette syndrome: Gene expression as a tool to discover drug targets
|
Liao, Isaac H.
|
|
2010
|
7 |
3 |
p. 302-306
|
article
|
| 75 |
Tourette Syndrome: Gene Expression as a Tool to Discover Drug Targets
|
Liao, Isaac H.
|
|
2010
|
7 |
3 |
p. 302-306
5 p.
|
article
|
| 76 |
Tourette Syndrome: Gene Expression as a Tool to Discover Drug Targets
|
Liao, Isaac H.
|
|
|
7 |
3 |
p. 302-306
|
article
|
Journal description